Syntekabio Obtains Patent for AI Drug Development Platform's Automatic Compound Derivative Generation Method

원본보기 아이콘

Syntekabio, an artificial intelligence (AI) new drug development specialist company (CEO Jeong Jong-seon), announced on the 22nd that it has completed the registration of a patent for the "Method for Generating Compound Derivatives for Target Proteins to Build an AI New Drug Platform."

The patent acquired by Syntekabio this time is a technology that can be used for computer-based prescreening (in silico prescreening) applied in the process of discovering effective new drug substances to build CADD (Computer Aided Drug Discovery) or AI new drug platforms. It relates to a method of generating various forms of derivatives from existing effective compounds for specific target proteins, the computer-generated (in silico) derivatives created by this method, and the AI new drug platform built using the method of generating derivatives.

The strength of this patent lies in the auto grow function, which allows scaffolds to automatically grow within the given target pocket. This function is also used to generate artificial virtual substances even when there are no known compounds in the protein pocket. Therefore, it is also utilized for the automatic generation of initial templates for virtual screening of tens of billions of compounds based on language models. The function of automatically growing molecular fragments in the pocket is a core advanced technology in new drug development, possessed only by some global pharmaceutical companies.

Furthermore, this patent enables the generation of derivatives with improved actual binding potential to the target protein through the derivative generation method, or derivatives with enhanced binding affinity to the target protein compared to effective compounds, or derivatives with improved effects on the activity of the target protein. Additionally, since the binding pose of compounds that can bind within the target space is derived during the derivative generation process, when molecular dynamics simulations are performed on the AI new drug platform, it is expected to enhance the possibility of deriving the optimal binding pose.

Jeong Jong-seon, CEO of Syntekabio, stated, "The patent acquired this time is the most core technology of our AI new drug development platform, an innovative technology that enables the search for optimal candidate substances through compound screening on massive amounts of data in a short time." He added, "We will continue to invest in research and technology to enhance corporate value through securing intellectual property rights."

Recently, Syntekabio has also accelerated its business in the United States by acquiring trademarks for ‘SYNTEKABIO LAUNCHPAD’ and ‘STB LAUNCHPAD’ in addition to this technology patent.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.